Know Cancer

forgot password

Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography in Hodgkin Lymphoma

18 Years
Open (Enrolling)
Hodgkin's Lymphoma

Thank you

Trial Information

Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography in Hodgkin Lymphoma

The proposed study is based on the repeated demonstration that patients with Hodgkin
lymphoma who attain a negative PET scan early in therapy (after one or 2 cycles of
chemotherapy) have a uniformly excellent outcome, with long term disease free survival of
90-95%. We propose to abbreviate chemotherapy in those patients showing a complete metabolic
response as measured by FDG-PET after one cycle of ABVD. These patients will undergo two
more cycles of ABVD chemotherapy, for a total of 3 cycles. Those patients failing to achieve
a complete metabolic response as demonstrated by residual FDG avidity will go off study and
be treated as per their primary treating physician.

Inclusion Criteria:

- Histologically documented classical Hodgkin lymphoma according to the WHO
Classification. Nodular lymphocyte predominant Hodgkin lymphoma is excluded

- No prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma

- Measurable disease must be present either on physical examination or imaging studies.
Any tumor mass measurable in two dimensions and > 2 cm is acceptable (or 1.5 cm if
0.5 cm slices are used as in spiral CT scans)

- Age ≥ 18

- Patients must have at least one hypermetabolic lesion identifiable on initial PET

- LVEF by ECHO or MUGA within institutional normal limits

- Initial laboratory data should be compatible with the administration of standard
doses of ABVD chemotherapy

Exclusion Criteria:

- Patient has no known HIV infection

- Patient is non-pregnant and non-lactating. Due to the teratogenic potential of the
agents used in this study, pregnant or nursing women may not be enrolled. Women and
men of reproductive potential should agree to use an effective means of birth control

- No other history of lymphoproliferative disorder or granulomatous disease

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival [PFS] at 36 months

Outcome Time Frame:

36 months

Safety Issue:


Principal Investigator

Rebecca Elstrom, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Weill Medical College of Cornell University


United States: Institutional Review Board

Study ID:




Start Date:

May 2010

Completion Date:

Related Keywords:

  • Hodgkin's Lymphoma
  • Hodgkin Disease
  • Lymphoma



Weill Cornell Medical CollegeNew York, New York  10021